The IDO1 inhibitor combos were one of the main immunotherapy competitors to the Cavatak/Keytruda combo in multiple cancer indications. The combo just failed a phase III trial in advanced melanoma.
Looks to me that Cavatak is now worth much more than $1.75/share ....
Www.endpts.com/keytruda-epacadostat-combo-crashes-in-phiii-melanoma-study-raising-questions-about-the-future-of-ido-for-incyte/
- Forums
- ASX - By Stock
- IDO1/Keytruda combo trial fails in melanoma
The IDO1 inhibitor combos were one of the main immunotherapy...
-
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VLA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online